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Abstract
Background: Kaposi’s sarcoma associated herpesvirus encoded viral FLICE inhibitory protein (vFLIP) K13 activates the NF-kB
pathway by binding to the NEMO/IKKc subunit of the IkB kinase (IKK) complex. However, it has remained enigmatic how
K13-NEMO interaction results in the activation of the IKK complex. Recent studies have implicated TRAF6, TAK1 and linear
ubiquitin chains assembled by a linear ubiquitin chain assembly complex (LUBAC) consisting of HOIL-1, HOIP and SHARPIN
in IKK activation by proinflammatory cytokines.
Methodology/Principal Findings: Here we demonstrate that K13-induced NF-kB DNA binding and transcriptional activities
are not impaired in cells derived from mice with targeted disruption of TRAF6, TAK1 and HOIL-1 genes and in cells derived
from mice with chronic proliferative dermatitis (cpdm), which have mutation in the Sharpin gene (Sharpin
cpdm/cpdm).
Furthermore, reconstitution of NEMO-deficient murine embryonic fibroblast cells with NEMO mutants that are incapable of
binding to linear ubiquitin chains supported K13-induced NF-kB activity. K13-induced NF-kB activity was not blocked by
CYLD, a deubiquitylating enzyme that can cleave linear and Lys63-linked ubiquitin chains. On the other hand, NEMO was
required for interaction of K13 with IKK1/IKKa and IKK2/IKKb, which resulted in their activation by ‘‘T Loop’’ phosphorylation.
Conclusions/Significance: Our results demonstrate that K13 activates the NF-kB pathway by binding to NEMO which results
in the recruitment of IKK1/IKKa and IKK2/IKKb and their subsequent activation by phosphorylation. Thus, K13 activates NF-
kB via a mechanism distinct from that utilized by inflammatory cytokines. These results have important implications for the
development of therapeutic agents targeting K13-induced NF-kB for the treatment of KSHV-associated malignancies.
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Introduction
Transcription factors of the nuclear factor-k B (NF-kB) family
regulate expression of hundreds of genes involved in the
inflammatory and immune response [1,2,3]. The classical NF-
kB complex is a heterodimer of the p65/RelA and p50 subunits
and is found in most cells in association with a family of inhibitory
proteins, called IkBs [4,5]. The IkB proteins are identified by the
presence of multiple ankyrin repeats and retain NF-kB in the
cytoplasm through the masking of the nuclear localization signal of
p65. Most of the diverse signaling pathways that activate NF-kB
converge on a multi-subunit IkB kinase (IKK) complex that
contains two catalytic subunits, IKK1/IKKa and IKK2/IKKb,
and a regulatory subunit, NEMO/IKKc [5,6]. The IKK complex
induces phosphorylation of IkB proteins that leads to their
ubiquitination and proteasomal-mediated degradation, allowing
the NF-kB subunits to enter the nucleus and turn on the
expression of their target genes [4].
A kinase complex composed of TAK1 and its associated
subunits TAB1, TAB2 and TAB3 has been reported to act as
the upstream kinase that activates the IKK complex by
targeting two serine residues located in the conserved ‘‘T loop’’
region of the kinase domains of IKK1/IKKa and IKK2/IKKb
[7,8]. Recently, various members of the E3 ligase family have
recently been implicated in NF-kB activation by participating in
ubiquitination processes not linked to protein degradation [8].
For example, one of the best characterized pathways that results
in NF-kB activation is the Tumor Necrosis Factor Receptor 1
(TNFR1) signaling pathway, which is activated by TNFa [9,10].
Binding of TNFa to TNFR1, results in the recruitment of
several adaptor proteins to the cytosolic domain of the receptor,
including the adaptor protein TRADD, E3 ligase TRAF2 and
cIAPs and kinases RIP, TAK1 and IKKs
[10,11,12,13,14,15,16]. These macromolecular complex results
in TRAF2 and cIAP1-mediated Lys63-linked polyubiquitination
of RIP, which then recruits the TAK1 complex through specific
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36601affinity of TAB2 and TAB3 for Lys63-linked chains [7,8,17].
Recently, another novel ubiquitin ligase complex, designated
LUBAC (linear ubiquitin chain assembly complex), was also
shown to be part of the TNFR1 signaling complex and to play
a key role in NF-kB activation by catalyzing the assembly of
linear ubiquitin chains [18,19,20,21].
Activation of NF-kB by IL1b and lipopolysaccharide involve
similar components. Binding of these ligands to their receptors
initially results in the recruitment of MyD88 [22]. Subsequently,
MyD88 recruits kinases IRAK4 and IRAK1 and E3 ligase
TRAF6, which results in IRAK1 phosphorylation, release of
IRAK1/TRAF6 and TRAF6 autoubiquitination [23,24,25].
Ubiquitinated TRAF6 is then believed to recruit the TAK1
complex and in concert with Ubc13, modify both TAK1 and
IRAK1 with Lys63-linked chains [26,27]. The final step in this
process involves recruitment of the IKKs through NEMO and
their phosphorylation/activation by TAK1 [26,28].
Kaposi’s sarcoma (KS) associated herpesvirus (KSHV), also
known as Human herpesvirus 8 (HHV8), is the commonest
cause of malignancy among patients with Acquired Immuno-
deficiency Syndrome [29,30]. Infection with KSHV has been
associated with KS, primary effusion lymphoma (PEL) and
multicentric Castleman’s disease (MCD) [31]. KSHV encodes
a vFLIP (viral FLICE inhibitory Protein), encoded by the open
reading frame K13, which is one of the few viral proteins to be
expressed in cells latently-infected with KSHV [32]. Based on
its structural homology to the prodomain of FLICE/caspase 8
[33], K13 was initially believed to be an inhibitor of FLICE/
caspase 8 (hence the name vFLIP) [33]. However, subsequent
work by our laboratory and others have demonstrated that the
main biological function of K13 is the activation of the NF-kB
pathway rather than inhibition of caspase 8/FLICE, and that it
utilizes this pathway to promote cellular survival, proliferation,
transformation and cytokine secretion [34,35,36,37,38]. We
recently demonstrated that K13 bypasses TRAF2 and TRAF3
and activates the NF-kB pathway by directly binding to the
NEMO subunit of the IKK complex [39]. However, it is not
clear how K13-NEMO interaction results in the activation of
the IKK complex. In this study, we have investigated the role
of TRAF6, TAK1 and LUBAC in K13-induced NF-kB
activation. We demonstrate that K13 activates the NF-kB
pathway independent of TRAF6 and TAK1. Furthermore,
linear polyubiquitination of NEMO is not required for K13-
induced NF-kB activation. Instead, NEMO is required for
mediating the interaction between K13 and IKK1 and IKK2.
Our results suggest that K13 activates the NF-kB pathway using
a mechanism distinct from that utilized by proinflammatory
cytokines.
Materials and Methods
Cell Lines and Reagents
293T, BC1, BCBL1, Jurkat and Namalwa cells were obtained
from ATCC (Manassas, VA). BCBL1 and Namalwa cells
expressing an empty vector and K13 have been described
previously [39,40]. Wild-type and NEMO-deficient cells have
also been described previously [41]. TRAF6
+/+ and TRAF6
2/2
mouse embryonic fibroblasts (MEFs) were gifts from Tak Mak
(University of Toronto, Canada) [24]. TAK1
+/+ and TAK1
2/2
MEFs were generously provided by Dr. Stephanie S. Watowich
(MD Anderson Cancer Center, Houston, Texas). HOIL-1
2/2
and cpdm cells were kindly provided by Dr. Kazuhiro Iwai
(Osaka University, Japan). TAK1 inhibitor 5Z-7-oxo-zeaenol was
purchased from Tocris Bioscience (Ellisville, MO), recombinant
TNFa and IL-1b were from Peprotech (Rocky Hill, NJ), and 4-
Hydroxytamoxifen (4OHT) was purchased from Sigma (St. Lois,
MO).
Plasmids
Plasmids encoding K13 and 4-Hydroxytamoxifen (4OHT)-
inducible K13-ER
TAM, CYLD, EDAR (ectodermal dysplasia
receptor) and NEMO have been described previously
[36,37,39,42,43]. Retroviral constructs expressing NEMO mu-
tants defective in linear ubiquitination were kindly provided by Dr.
Ivan Dikic (Goethe University Medical School). Recombinant
retroviruses were generated and used to generate polyclonal
populations of stably transduced MEFs following selection with
puromycin essentially as described previously [44].
Luciferase Reporter Assay
293T cells were transfected in a 24-well plate with various test
plasmids along with an NF-kB luciferase reporter construct
(75 ng/well) and a pRSV/LacZ (b-galactosidase) reporter con-
struct (75 ng/well) as described previously [42]. Cells were lysed
24–36 h later, and extracts were used for the measurement of
firefly luciferase and b-galactosidase activities, respectively.
Luciferase activity was normalized relative to the b-galactosidase
activity to control for the difference in the transfection efficiency.
Transient transfection of MEFs and measurement of luciferase
activity was performed essentially as described previously [45].
Briefly, MEFs were transfected in duplicate using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) in a 24-well plate with the
various test plasmids along with an NF-kB/luciferase reporter
construct (75 ng/well) and a Renilla luciferase reporter construct
(phRG-TK, 75 ng/well, Promega, Madison, WI). The cells were
lysed 48 hours later, and extracts were used for the measurement
of firefly and Renilla luciferase activities as described in the Dual-
LuciferaseH Reporter (DLR
TM) Assay system from Promega.
Firefly luciferase activity was normalized relative to the Renilla
luciferase activity to control for the difference in the transfection
efficiency.
Western Blot
Western blot analysis was performed essentially as described
previously [34]. Primary antibodies used in these experiments
were: NEMO, Total-IkBa, Rel B, TRAF6 (Santa Cruz Bio-
technology, Santa Cruz, CA); tubulin, M2 FLAG (Sigma, St.
Louis, MO), and phospho-TAK1, phospho-IkBa and A20 (Cell
Signaling, Danvers, MA). A mouse monoclonal antibody against
K13 (8F6) was raised in our laboratory.
NF-kB DNA-binding Assays
The NF-kB subunit composition of the K13-induced NF-kB
complexes in wild-type and TAK1
2/2 MEFs was determined with
an NF-kB ELISA kit (TransAM NF-kB; Active Motif, Carlsbad,
CA) according to the manufacturers’ instructions. The electro-
phoretic mobility shift assay was performed as described previously
[34].
Pathscan ELISA Assay
The PathScan Phospho-IKKa (Ser176/180), Phospho-IKKb
(Ser177/181) sandwich ELISA Kits and PathScan Phospho-IkBa
(Ser32) sandwich ELISA antibody pair (Cell Signaling, Danvers,
MA) were used to detect endogenous levels of IKKa, IKKb and
IkBa proteins when phosphorylated at Ser176/180, Ser177/181
and Ser32, respectively.
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Two-tailed paired Student’s t test was used to test for differences
between two groups. Differences with a p#0.05 were considered
as statistically significant. All experiments were repeated a mini-
mum of three times with duplicate/triplicate samples.
Results
TRAF6 is not Required for K13-induced NF-kB Activation
Different members of the TRAF family are required for NF-kB
activation by distinct stimuli. Thus, while TRAF2 is known to be
required for NF-kB activation by TNFa, TRAF6 has been
implicated in the activation of this pathway signaling via
interleukin 1 and Toll like receptors [46,47]. We have recently
demonstrated that TRAF2 is not involved in K13-induced NF-kB
activation [39]. To rule out the involvement of TRAF6 in K13-
induced NF-kB activity, we transiently transfected TRAF6
+/+ and
TRAF6
2/2 MEFs with an empty vector or a K13 expression
construct and examined the activation of a cotransfected NF-kB-
Luc reporter construct. As shown in Figure 1A, we observed near
equivalent K13-induced NF-kB-Luc activity in the TRAF6
+/+ and
TRAF6
2/2 MEFs. Essentially similar results were obtained when
the experiment was repeated using the K13-ER
TAM construct
followed by treatment with 4OHT (Fig. 1B). Finally, we generated
stable populations of TRAF6
+/+ and TRAF6
2/2 MEFs expressing
an empty vector or the K13-ER
TAM construct. The mutated
estrogen receptor (ER
TAM) in the K13-ER
TAM construct does not
bind to its physiological ligand estrogen but binds with very high
affinity to the synthetic ligand 4OHT (4-hydroxytamoxifen) and
allows the control of K13 activity in a 4OHT-dependent fashion
[48]. We treated the resulted cells with 4OHT to activate K13
activity and assessed the activation of the NF-kB pathway by
measuring the upregulation of A20, a protein known to be induced
by K13-induced NF-kB activity [49]. As shown in Fig. 1C,
treatment with 4OHT resulted in equivalent upregulation of A20
in the TRAF6
+/+ and TRAF6
2/2, which argues against the
involvement of TRAF6 in K13-induced NF-kB activation.
TAK1 is not Required for K13-induced NF-kB Activation
TRAF6 is believed to activate NF-kB by activating TAK1,
which in turn phosphorylates and activates the IKK complex
resulting in NF-kB activation [7,8]. TAK1 was also shown to be
required for NF-kB activation by KSHV-encoded viral G protein
coupled receptor (vGPCR) [50]. To study the role of TAK1 in
K13-induced NF-kB activation, we took advantage of murine
embryonic fibroblast (MEFs) cells deficient in this protein. We
used retroviral-mediated gene transfer to generate stable pools of
wild-type and TAK1-deficient MEFs expressing an empty vector
and FLAG-tagged K13. An immunoblot analysis confirmed
equivalent expression of the K13 in the wild-type (WT) and
TAK1
2/2 MEFs (Fig. 2A). The expression of K13 in the wild-type
(WT) and TAK1
2/2 MEFs, however, was lower than its expression
in the KSHV-infected BC1 cell line (Fig. 2A). We subsequently
used an electrophoretic mobility shift assay (EMSA) to compare
the ability of K13 to activate the NF-kB pathway in the two cell
lines. Consistent with the known ability of K13 to activate the NF-
kB pathway, ectopic expression of K13 in the TAK
+/+ MEFs
resulted in increased nuclear NF-kB DNA binding activity
(Fig. 2B). However, an equivalent increase in NF-kB DNA
binding activity was observed upon ectopic expression of K13 in
the TAK1
2/2 cells (Fig. 2B). To confirm these results, we
generated stable clones of WT and TAK1
2/2 MEFs expressing
the K13-ER
TAM fusion protein and used an ELISA-based DNA-
binding assay to study the subunit composition of NF-kB
complexes induced following treatment with 4OHT in the two
cell lines. This assay revealed that p65 and p50 were the major
NF-kB subunits induced by 4OHT in both the WT and TAK1
2/2
K13-ER
TAM expressing MEFs, with modest induction of p52,
RelB and cRel subunits (Fig. 2C). Thus, TAK1 has no major effect
on either the amount or subunit composition of NF-kB complexes
induced by K13. We next examined the effect of TAK1 on K13-
induced NF-kB transcriptional activity. For this purpose, we
transiently transfected an empty vector or a K13-ER
TAM-fusion
construct in wild-type and TAK1
2/2 MEFs and measured NF-kB
transcriptional activation using an NF-kB luciferase reporter assay.
As shown in Figure 2D, transfection of TAK
+/+ MEFs with K13-
ER
TAM followed by treatment with 4OHT resulted in a significant
increase in NF-kB-Luc reporter activity. However, 4OHT
treatment of K13-ER
TAM-transfected TAK
2/2 MEFs also led to
an equivalent increase in NF-kB-Luc activity, thereby demon-
strating that TAK1 is not required for K13-induced NF-kB
transcriptional activation.
K13 does not Induce TAK1 Phosphorylation
Human T-cell Leukemia virus 1 (HTLV-1) encoded Tax
protein resembles K13 in activating the NF-kB pathway by
binding to NEMO [51]. It was recently shown that TAK1 is
constitutively activated by Thr-187 phosphorylation in Tax-
positive HTLV-1-transformed T cells [52]. Therefore, to examine
whether K13 would similarly induce TAK1 Thr-187 phosphor-
ylation, we used retroviral-mediated gene transfer and generated
polyclonal populations of two lymphoma cell lines, BCBL1 and
Namalwa, expressing an empty vector and FLAG-K13. We chose
these cell lines as they possess low to none constitutive NF-kB
activity endogenously (Fig. 2E). Ectopic expression of K13 in both
BCBL1 and Namalwa cells failed to induce phosphorylation of
TAK1 as determined by Western blotting with a phospho-
Thr184/Thr187 TAK1 antibody, whereas treatment with TNFa
successfully did so (Fig. 2F). Thus, in contrast to HTLV-1
oncoprotein Tax, K13 does not induce TAK1 phosphorylation.
K13-induced NF-kB is not Blocked by a Specific Inhibitor
of TAK1
5Z-7-Oxozeaenol,aresorcycliclactoneoffungalorigin,isapotent
and selective inhibitor of TAK1 [53]. To confirm the lack of
involvement of TAK1 in K13-induced NF-kB activity, we studied
the effect of increasing doses of 5Z-7-Oxozeaenol treatment on
4OHT induced NF-kB luciferase activity in 293NF-kB-Luc- K13-
ER
TAM cells which stably express an NF-kB-driven luciferase
reporter construct and the K13-ER
TAM fusion protein. As shown in
Figure 2G, treatment with up to 1 mM 5Z-7-Oxozeaenol had no
significant inhibitory effect on 4OHT-induced NF-kB reporter
activity. In comparison, 0.5 mM 5Z-7-Oxozeaenol significantly
inhibited TNFa and IL-1b-induced NF-kB activity in the 293NF-
kB-Luc reporter cells (Fig. 2H). Taken collectively with previous
studies, the above results confirm that TAK1 is not required for
K13-induced NF-kB activation.
HOIL-1 is not Essential for K13-induced NF-kB Activation
Recently, a novel ubiquitin ligase complex, designated LUBAC
(linear ubiquitin chain assembly complex), which is composed of
two RING finger proteins, HOIL-1 (also known as RBCK1) and
HOIP, and SHARPIN (SHANK-associated RH domain interact-
ing protein in postsynaptic density) was shown to play a key role in
the activation of the NF-kB pathway by binding to NEMO and
conjugating linear polyubiquitin chains onto its specific Lys
residues [18,19,20]. We used HOIL-1-null MEFs to test the
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induced NF-kB activation. For this purpose, we generated stable
populations of wild-type and HOIL-1-null MEFs expressing and
empty vector and FLAG-tagged K13-ER
TAM construct. A
Western blot analysis confirmed expression of the K13-ER
TAM-
fusion protein in both wild-type and HOIL-1
2/2 MEFs, with
slightly higher expression in the latter (Fig. 3A). We measured NF-
kB transcriptional activation in the resulting cells with and without
4OHT treatment using an NF-kB luciferase reporter assay. As
shown in Figure 3B, we observed robust activation of NF-kB-Luc
activity upon 4OHT treatment in both the WT-K13-ER
TAM and
HOIL-1
2/2 K13-ER
TAM cells, arguing against the possibility that
HOIL-1 is required for K13-induced NF-kB activity. Indeed, the
HOIL-1
2/2 K13-ER
TAM cells showed a greater increase in NF-
kB-Luc activity as compared to the WT-K13-ER
TAM cells upon
4OHT treatment, which was probably due to the higher level
expression of the K13-ER
TAM protein in the former. Consistent
with the lack of requirement of HOIL-1 in K13-induced NF-kB
activity, we observed equivalent increase in nuclear p65 DNA-
binding activity in the wild-type and HOIL-1
2/2 MEFs upon
ectopic K13 expression (Fig. 3D–E). In contrast, TNFa-induced
NF-kB-Luc and p65 DNA binding activities were markedly
reduced in HOIL-1
2/2 MEFs (Fig. 3C, 3F). Finally, to confirm the
lack of involvement of HOIL-1 in K13-induced NF-kB activity, we
used Western blot analysis to compare the phosphorylation of
IkBa and expression of A20 and RelB, two proteins that are
known to be upregulated by the NF-kB pathway, in the wild-type
and HOIL-1
2/2 MEFs stably expressing K13. As shown in
Figure 3G, we observed increased phosphorylation of IkBa and
upregulation of A20 and RelB in both wild-type and HOIL-1
2/2
MEFs upon ectopic K13 expression, which argues against an
essential role of HOIL-1 in K13-induced NF-kB activity. Indeed,
K13-expressing HOIL-1
2/2 MEFs showed slightly more IkBa
phosphorylation and A20 and RelB expression as compared to the
K13-expressing wild-type MEFs. This was probably due to
slightly higher level of ectopic K13 expression in the latter
(Fig. 3G).
Sharpin is not Essential for K13-induced NF-kB Activation
Mutation in Sharpin (SHANK-associated RH domain interact-
ing protein in postsynaptic density) gene are responsible for cpdm
(chronic proliferative dermatitis) phenotype in mice that resembles
the phenotype of patients with X-linked hyper-IgM syndrome and
hypohydrotic ectodermal dysplasia (XHMED), which is caused by
mutations in NEMO [54]. SHARPIN shows significant similarity
to HOIL-1 and was recently shown to be a component of LUBAC
and to be required for linear ubiquitination of NEMO and NF-kB
activation [19,20,21]. To examine whether SHARPIN is required
for K13-induced NF-kB activity, we examined the ability of K13
to activate an NF-kB-Luc reporter construct in cpdm MEFs. As
shown in Figure 4A, transient transfection of K13 strongly
activated the NF-kB-Luc reporter in cpdm MEFs, whereas
treatment with TNFa failed to do so. We also generated stable
populations of wild-type and cpdm MEFs expressing K13 and
observed equivalent increase in the nuclear p65/RelA DNA-
binding activity upon ectopic K13 expression (Fig. 4B). Finally,
ectopic K13 expression also resulted in an increase in IkBa
phosphorylation and enhanced expression of the NF-kB target
proteins A20 and RelB in the cpdm MEFs (Fig. 4C). Taken
collectively, the above results demonstrate that SHARPIN is not
essential for K13-induced NF-kB activity.
NEMO Mutants Defective in Binding to Linear
Polyubiquitin Chains Support K13-Induced NF-kB
NEMO was recently shown to selectively bind linear ubiquitin
chains and NEMO mutants V293A/Y301A/K302A and F305A
that are defective in binding linear ubiquitin chains were shown to
be incapable of supporting NF-kB activation by TNFa and other
agonists [55]. Therefore, as an independent test of the involvement
Figure 1. TRAF6 is not required for K13-induced NF-kB activation. A. TRAF6
+/+ and TRAF6
2/2 MEFs were transfected with a control vector or
vector encoding K13 along with an NF-kB-Luc construct (75 ng/well) and a Renilla reporter construct (75 ng/well, normalization control) using
Lipofectamine 2000-mediated transaction. The luciferase reporter assay was performed 48 hours post transfection essentially as described in
‘‘Materials and Methods’’ section. Asterisks (*) indicate significance at levels of p#0.05. B. TRAF6
+/+ and TRAF6
2/2 MEFs were transfected with
a control vector or a vector encoding K13-ER
TAM along with an NF-kB-Luc construct and a Renilla reporter construct. The transfected cells were
subsequently treated with 4OHT (20 nM) for 48 hours and the reporter assays performed as described above. The values shown are averages
(mean6SE) of one representative experiment out of three in which each transfection was performed in duplicate. Asterisks (*) indicate significance at
levels of p#0.05. C. TRAF6
+/+ and TRAF6
2/2 MEF cells expressing an empty vector or the FLAG-tagged K13-ER
TAM treated with 4OHT were examined
by immunoblot analysis for upregulation of A20. Tubulin was used as a loading control.
doi:10.1371/journal.pone.0036601.g001
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reconstituted NEMO-deficient MEFs with an empty vector, wild-
type NEMO, NEMO-V293A/Y301A/K302A and NEMO-
F305A using retroviral mediated gene transfer (Fig. 5A). In the
resulting cells, we stably expressed an empty vector and K13
(Fig. 5B). After confirming the equivalent expression of the
transduced proteins by Western blotting, we examined the status
of the NF-kB by measuring nuclear p65/RelA DNA binding
activity. Ectopic expression of K13 failed to induce nuclear p65/
RelA DNA binding activity in the NEMO
2/Y MEFs reconstituted
with an empty vector, but resulted in approximately 3 fold increase
in the nuclear p65/RelA DNA binding activity in those
reconstituted with the wild-type NEMO, thereby confirming that
NEMO is required for K13-induced NF-kB activation (Fig. 5C).
More importantly, we observed an equivalent increase in K13-
induced nuclear p65/RelA DNA binding activity in NEMO
2/Y
MEFs reconstituted with NEMO-V293A/Y301A/K302A and
NEMO-F305A mutants, respectively (Fig. 5C). Thus, binding of
NEMO to linear polyubiquitin chain is not required for K13-
induced NF-kB activation.
CYLD Fails to Block K13-induced NF-kB Activity
The deubiquitylating enzyme CYLD, a negative regulator of
the NF-kB pathway, can cleave linear ubiquitin chains [56,57].
Figure 2. K13 activates NF-kB pathway without involving TAK1. A. Immunoblot showing expression of ectopically expressed FLAG-tagged
K13 in TAK1
+/+ and TAK1
2/2 MEFs and endogenous K13 in BC1 cell line. B. Status of NF-kB pathway, as measured by an EMSA in TAK1
+/+ and TAK1
2/2
MEF cells stably expressing vector and K13. The position of the induced NF-kB complexes is marked by an asterisk, while an arrow marks the position
of the constitutive complexes. C. The NF-kB subunits composition of the K13-induced nuclear NF-kB complexes in the wild-type and TAK1
2/2 MEFs
was determined with an ELISA-based DNA-binding assay performed in triplicate. Asterisks (*) indicate significance at levels of p#0.05. D. TAK1
+/+ and
TAK1
2/2 MEFs expressing FLAG-K13-ER
TAM were transfected with NF-kB-Luc and Renilla reporter constructs and subsequently treated with 4OHT
(20 nM) for 48 hours and the reporter assays performed as described in Figure 1A. Asterisks (*) indicate significance at levels of p#0.05. E. Nuclear
extracts from Jurkat, BC1, BCBL1 and Namalwa were used for the measurement of p65 DNA-binding activity using an ELISA-based assay. F. Lack of
phosphorylation of TAK1 by K13. Cell lysates prepared from BCBL1 and Namalwa cells expressing an empty vector or FLAG-K13 were probed with an
antibody to detect phosphorylation of TAK1. Vector cells treated with TNFa were used a positive control. The blot was re-probed with FLAG and
Tubulin antibodies to check the expression of the transduced K13 and equal protein loading, respectively. G2H. Treatment with TAK1 inhibitor 5Z-7-
oxo-zeaenol had no effect on 4OHT induced NF-kB-Luc activity in 293-K13-ER
TAM-NF-kB-Luc cells but effectively blocked TNFa and IL1b induced NF-
kB-Luc activity.
doi:10.1371/journal.pone.0036601.g002
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TAM in wild-type and HOIL-1
2/2
MEF was confirmed with Western blotting. The blot was re-probed with a tubulin antibody to show equal protein loading. B. Wild-type and HOIL-1
2/
2 MEFs stably expressing FLAG-K13-ER
TAM were transfected with NF-kB-Luc and Renilla reporter constructs. Cells were subsequently treated with
4OHT (20 nM) for 48 hours and the luciferase reporter assay was performed essentially as described in Figure 1A. Asterisks (*) indicate significance at
levels of p#0.05 as compared to vehicle-treated cells. C. Wild-type and HOIL-1
2/2 MEFs were transfected with NF-kB-Luc and Renilla reporter
constructs and 6 hours post-transfection, these cells were treated with mTNF-a (10ng/ml) for 18 hours and the luciferase reporter assay was
performed essentially as described in Figure 1A. D. Expression of transduced FLAG-tagged K13 in wild-type and HOIL-1
2/2 MEFs was examined by
immunoblot analysis; tubulin was used as a loading control. E. Nuclear p65 DNA binding activities in the nuclear extracts of wild-type and HOIL-1
2/2
MEFs expressing an empty vector or FLAG-K13. Asterisks (*) indicate significance at levels of p#0.05 as compared to vector cells. F. Nuclear p65 DNA
binding activities in the nuclear extracts of wild-type and HOIL-1
2/2 MEFs following treatment with murine TNFa. G. Wild-type and HOIL-1
2/2 MEFs
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Ub chains in K13-induced NF-kB activation, we tested the ability
of CYLD to block K13-induced NF-kB-Luc reporter activity. We
used TNFR1, CD40, and EDAR (Ectodermal Dysplasia Receptor)
as controls for this experiment since NF-kB activation by these
receptors is known to require linear polyubiquitination or is
inhibited by CYLD [58,59]. As shown in Figure 6A-D,
coexpression of CYLD had no effect on K13-induced NF-kB
activity but effectively blocked TNFR1, CD40 and EDAR-
induced NF-kB activity. Thus, in contrast to the receptors of the
TNFR family, K13-induced NF-kB is not dependent on linear
ubiquitin chains.
Essential Role of NEMO in Mediating K13-IKK Interaction
and IKK Activation
We and others have previously demonstrated that K13 interacts
with NEMO and NEMO is essential for K13-induced NF-kB
activation [34,60]. The studies in the preceding section clearly
demonstrate that TAK1, TRAF6 and linear polyubiquitination of
NEMO are not involved in K13-induced NF-kB activation.
Therefore, to explain the role of NEMO in K13-inducd NF-kB
activation, we tested the hypothesis that NEMO mediates the
interaction between K13 and IKK1 and IKK2. For this purpose,
FLAG-tagged K13 was immunoprecipitated from the WT and
NEMO-deficient Jurkat cells using Flag or control antibody beads
and its interaction with endogenously expressed NEMO, IKK1
and IKK2 was examined by Western blot analysis. As shown in
expressing FLAG-K13 were examined for NF-kB activation by Western blot analysis using antibodies against phospho-IkBa, Total IkBa, A20 and RelB.
The blot was re-probed with FLAG and Tubulin antibodies to check the expression of the transduced K13 and equal protein loading, respectively.
doi:10.1371/journal.pone.0036601.g003
Figure 4. SHARPIN is not required for K13-induced NF-kB activation. A. MEFs deficient in SHARPIN (cpdm) were able to activate NF-kB
reporter activity in the presence of K13, but not with TNFa. Asterisks (*) indicate significance at levels of p#0.05. B. SHARPIN is not required for K13-
induced NF-kB p65 DNA binding as determined by ELISA. Asterisks (*) indicate significance at levels of p#0.05 as compared to vehicle-treated cells.
C. Total cell lysates from wild-type, and cpdm MEF stably expressing an empty vector or FLAG-tagged K13 were used to examine the requirement of
SHARPIN on K13-induced NF-kB activation by upregulation of expression of A20, RelB, phosphorylation of IkBa and degradation of total IkBa. The
expression of the FLAG-tagged K13 protein and equal protein loading was confirmed by blotting with FLAG and Tubulin antibodies, respectively.
doi:10.1371/journal.pone.0036601.g004
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IKK2 was readily detected in samples immunoprecipitated with
Flag antibody from wild-type Jurkat cells, no significant interaction
between K13 and IKK1 or IKK2 was observed in the NEMO-
deficient Jurkat cells, Stimulation of cells with TNFa or IL-1
induces recruitment of IKK1 and IKK2 to NEMO and their
subsequent phosphorylation and activation [61,62]. The relevant
phosphorylation sites in IKK1 and IKK2 have been mapped to
regions in their catalytic domain that shares strong homology with
‘‘T loop’’ regulatory sequences found in the members of the
mitogen activated protein kinase kinase (MAP2K) family of
enzymes [61,62]. These sites include Ser176 and Ser180 for
IKK1 and Ser177 and Ser181 for IKK2. We next examined if
recruitment of IKK1 and IKK2 to the K13-NEMO complex is
also associated with ‘‘T Loop’’ phosphorylation of IKK1, IKK2 or
both. The K13-ER
TAM expressing MEFs were treated with
4OHT and phosphorylation status of IKK1 and IKK2 was
determined using Pathscan phospho-IKK1(Ser176/180) and
phospho-IKK2 (Ser177/181) ELISA kits, respectively. As shown
in Figure 7C, 4OHT treatment of K13-ER
TAM cells resulted in
a significant increase in ‘‘T loop’’ phosphorylation of IKK1, IKK2
as compared to the untreated cells. The K13-induced increased
‘‘T loop’’ phosphorylation of IKK1 and IKK2 was also associated
with increased phosphorylation of IkBa. Thus, recruitment of
IKK1 and IKK2 to the K13-NEMO complex results in their
activation by ‘‘T loop’’ phosphorylation.
Discussion
K13 is known to activate the NF-kB pathway by binding to
activating the ,700 kDa IKK complex consisting of IKK1/
IKKa, IKK2/IKKb and NEMO/IKKc [34]. We have previously
Figure 5. The ability of K13 to activate NF-kB pathway does not require linear polyubiquitination of NEMO. A–B. MEF NEMO
2/Y cells
were stably transduced with wild-type NEMO and two NEMO mutants defective in linear ubiquitination of NEMO (NEMO-Y293A/Y301A/K302A and
NEMO-F305A) and their expression was confirmed by immunoblotting using NEMO antibody. These cells were further transduced with either an
empty retroviral vector or a retroviral vector expressing FLAG-tagged K13 and their expression was determined by immunoblotting with FLAG
antibody. The blot was re-probed with a tubulin antibody to show equal loading of protein. C. Upon expression of K13, these cells were able to
activate NF-kB p65 DNA binding as determined by ELISA. The values shown are averages (mean6SE) of one representative experiment out of three in
which the level of p65 DNA binding was measured in triplicate. Asterisks (*) indicate significance at levels of p#0.05.
doi:10.1371/journal.pone.0036601.g005
Figure 6. Deubiquitinating enzyme CYLD, a negative regulator of NF-kB pathway does not block K13-induced NF-kB activity. A–D.
The 293T cells were co-transfected with a control vector or vectors encoding FLAG-K13, TNFR1, CD40 and EDAR (250 ng/ml) and a CYLD plasmid
construct (750 ng/well) along with NF-kB-Luc reporter construct (75 ng/well) and a pRSV/LacZ (b-galactosidase) reporter construct (75 ng/well), and
the reporter assay performed as described in ‘‘Materials and Methods’’ The values shown are averages (mean6SE) of one representative experiment
out of three in which each transfection was performed in duplicate.
doi:10.1371/journal.pone.0036601.g006
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[34,45]. However, the exact mechanism by which K13-NEMO
interaction results in the activation of the IKK complex and the
NF-kB pathway is not clear. In a recent study, we demonstrated
that TRAF2, which is required for NF-kB activation by TNFa,i s
not required for the interaction of K13 with NEMO and for K13-
induced NF-kB activation [39]. In this report, we have excluded
the involvement of TRAF6, which has been implicated in NF-kB
activation during signaling emanating from IL-1 and Toll like
receptors [46,47], in K13-induced NF-kB activation. Taken
collectively, these studies support the model that K13 bypasses
TRAFs and directly interacts with the IKK complex to activate
the NF-kB pathway. This model is consistent with previous studies
demonstrating a direct interaction between K13 and NEMO/
IKKc in GST-pull down and yeast two-hybrid assays [18], and the
recently described crystal structure of the K13-NEMO complex
[63].
We next asked the question how the interaction of K13 with
NEMOresultsintheactivation oftheIKKcomplexandtheNF-kB
pathway. Genetic and pharmacological studies have implicated
TAK1 as the upstream kinase responsible for the activation of the
IKK complex during NF-kB activation by pro-inflammatory
cytokines [7,8]. A recent study also showed that TAK1 is required
for NF-kB activation by KSHV-encoded viral G protein coupled
receptor (vGPCR) [50]. In contrast, we found no defect in K13-
induced NF-kB DNA-binding and transcriptional activities in
TAK1-deficient cells. The lack of involvement of TAK1 in K13-
induced NF-kB activity was further supported by our studies with
5Z-7-oxo-zeaenol, a specific inhibitor of TAK1, which failed to
block K13-induced NF-kB transcriptional activity.
Recent studies have implicated LUBAC-mediated linear
polyubiquitination in NF-kB activation by proinflammatory
cytokines [18,19,20]. Depending on their position relative to the
substrate, the ubiquitin monomers in uniquitin chains can be
described as Ubdistal or Ubproximal subunits [55]. A crystal structure
of NEMO in complex with linear ubiquitin molecules has
demonstrated that distinct residues of NEMO interact with
Ubdistal and Ubproximal subunits [55]. A recent study reported that
reconstitution of a NEMO-deficient clone of mouse 70Z/3
lymphoma cells, designated 1.3E2, with a murine NEMO mutant
that is defective in binding to Ubdistal (NEMO-F312A) resulted
in restoration of K13-induced NF-kB activation [64]. To confirm
the lack of involvement of linear polyubiquitination in K13-
induced NF-kB activation, we took advantage of cells that are
deficient in two essential components of LUBAC, an enzyme
complex required for linear polyubiquitination. Our results with
HOIL-1
2/
2 and cpdm MEFs, rule out the requirement of LUBAC-
induced linear polyubiquitination in K13-induced NF-kB activa-
tion. The lack of requirement of linear polyubiquitination in K13-
induced NF-kB activation was further supported by our results
showing that CYLD, a deubiquitylating enzyme that can cleave
linear ubiquitin chains, cannot block K13-induced NF-kB activity.
Taken collectively, the above results demonstrate that linear
polyubiquitination is not required for K13-induced activation of
the IKK complex and the NF-kB pathway.
In addition to its interaction with linear ubiquitin chains,
NEMO has been shown to interact with Lys63-linked ubiquitin
chains [8,65] and it has been recently suggested that both types of
chains cooperate for optimal activation of the NF-kB pathway by
proinflammatory cytokines [66]. Interestingly, a F312A mutation
in human NEMO, which corresponds to the F305A mutation in
mouse NEMO tested in this study, was shown to be defective in
binding to Lys63-linked ubiqutin chains [8], which suggests that
K13 activates NF-kB independent of Lys63-linked chains as well.
This hypothesis is further supported by our results showing that
K13-induced NF-kB is not blocked by CYLD, a deubiquitylating
enzyme that cleaves both linear and Lys63-linked ubiquitin chains
[57,67].
Based on the lack of involvement of TRAF6, TAK1 and
LUBAC in K13-induced NF-kB activation, we support a model
according to which the interaction between K13 and NEMO is
direct and is not mediated via the TRAF family members or the
linear ubiquitin chains. We further demonstrate that binding of
K13 to NEMO is required for recruitment of IKK1 and IKK2 to
Figure 7. NEMO-mediated recruitment of IKK1 and IKK2 to K13 and their activation by ‘‘T loop’’ phosphorylation. A. Co-
immunoprecipitation assay showing NEMO is essential for mediating the interaction of K13 with IKK1 and IKK2. FLAG-tagged K13 was
immunoprecipitated from WT and NEMO-deficient Jurkat cells using control (C) and FLAG (F) antibody beads and presence of co-immunoprecipitated
IKK1, IKK2 and NEMO detected by immunoblotting. B. MEFs expressing K13-ER
TAM were treated with 4OHT and phosphorylation status of IKK1, IKK2
and IkBa was determined using Pathscan phospho-IKK1 (Ser176/180), phospho-IKK2 (Ser177/181), phosphor-IkBa (Ser32) ELISA kits, respectively.
doi:10.1371/journal.pone.0036601.g007
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according to which binding of K13 to NEMO manipulates the
latter into an open conformation that facilitates the recruitment of
IKK1 and IKK2 and their subsequent activation by ‘‘T loop’’
phosphorylation.
Specific inhibitors of IKK (particularly IKK2) that can
selectivity block NF-kB pathway are being developed by several
pharmaceutical companies [68]. However, since the NF-kB
pathway plays a key role in normal immune response [69], the
clinical utility of such agents in KSHV-associated lymphoproli-
ferative disorders is likely to be limited by their potential toxicity.
For example, in vivo administration of ML120B, a small molecule
selective inhibitor of IKK2, led to rapid depletion of T and B cells
[70]. Although no IKK1-selective inhibitor has been described to
date, genetic studies suggest that IKK1 may similarly play an
essential role in lymphocyte development and function [71]. As
patients with KSHV-associated malignancies are usually immu-
nosuppressed, the deleterious effect of IKK inhibitors on
lymphocyte number and function is of potential concern.
Therefore, we believe that rather than blocking NF-kB pathway
globally, the ideal agent for the treatment of KSHV-associated
lymphoproliferative disorders should selectively block K13-in-
duced NF-kB activation. Our results showing that K13 activates
the NF-kB pathway via a mechanism distinct from that utilized by
immune and inflammatory cytokines suggest that it may be
possible to design such an agent that will selectively block K13-
induced NF-kB while sparing the physiological activation of this
pathway required for normal lymphocyte development, survival
and function.
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